Rett syndrome: from bed to bench.

[1]  S. Cobb,et al.  Synaptic plasticity deficits in an experimental model of rett syndrome: long-term potentiation saturation and its pharmacological reversal , 2011, Neuroscience.

[2]  W. Kaufmann,et al.  Rett syndrome: Revised diagnostic criteria and nomenclature , 2010, Annals of neurology.

[3]  J. Davies,et al.  Gene therapy for cystic fibrosis. , 2010, Proceedings of the American Thoracic Society.

[4]  J. Prieto,et al.  Gene therapy for liver cancer: clinical experience and future prospects. , 2010, Current opinion in molecular therapeutics.

[5]  P. Malik,et al.  Therapy for β‐globinopathies: a brief review and determinants for successful and safe correction , 2010, Annals of the New York Academy of Sciences.

[6]  J. Eubanks,et al.  Diminished prevalence but preserved synaptic distribution of N-methyl-d-aspartate receptor subunits in the methyl CpG binding protein 2(MeCP2)-null mouse brain , 2010, Neuroscience.

[7]  D. Kunze,et al.  Exogenous Brain-Derived Neurotrophic Factor Rescues Synaptic Dysfunction in Mecp2-Null Mice , 2010, The Journal of Neuroscience.

[8]  James H. Eubanks,et al.  Alterations of cortical and hippocampal EEG activity in MeCP2-deficient mice , 2010, Neurobiology of Disease.

[9]  Robert S. Illingworth,et al.  Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. , 2010, Molecular cell.

[10]  S. Albelda,et al.  Gene therapy for mesothelioma and lung cancer. , 2010, American journal of respiratory cell and molecular biology.

[11]  S. Nelson,et al.  Pathophysiology of Locus Ceruleus Neurons in a Mouse Model of Rett Syndrome , 2009, The Journal of Neuroscience.

[12]  S. Nelson,et al.  Intact Long-Term Potentiation but Reduced Connectivity between Neocortical Layer 5 Pyramidal Neurons in a Mouse Model of Rett Syndrome , 2009, The Journal of Neuroscience.

[13]  G. Voutsinas,et al.  Molecular targeting and gene delivery in bladder cancer therapy. , 2009, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[14]  P. Dirks,et al.  MECP2 Isoform-Specific Vectors with Regulated Expression for Rett Syndrome Gene Therapy , 2009, PloS one.

[15]  E. Masliah,et al.  Widespread changes in dendritic and axonal morphology in Mecp2‐mutant mouse models of rett syndrome: Evidence for disruption of neuronal networks , 2009, The Journal of comparative neurology.

[16]  P. Huppke,et al.  Suppression of Nonsense Mutations in Rett Syndrome by Aminoglycoside Antibiotics , 2009, Pediatric Research.

[17]  D. Harvey,et al.  Rett Syndrome Astrocytes Are Abnormal and Spread MeCP2 Deficiency through Gap Junctions , 2009, The Journal of Neuroscience.

[18]  W. Mobley,et al.  Evidence for both neuronal cell autonomous and nonautonomous effects of methyl-CpG-binding protein 2 in the cerebral cortex of female mice with Mecp2 mutation , 2009, Neurobiology of Disease.

[19]  G. Mandel,et al.  Non–cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology , 2009, Nature Neuroscience.

[20]  Nathan R. Wilson,et al.  Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice , 2009, Proceedings of the National Academy of Sciences.

[21]  Jennifer M. Moriuchi,et al.  Environmental enrichment alters locomotor behaviour and ventricular volume in Mecp2 1lox mice , 2009, Behavioural Brain Research.

[22]  Michael P. Stryker,et al.  Reversing Neurodevelopmental Disorders in Adults , 2008, Neuron.

[23]  H. Zoghbi,et al.  Genetic Modifiers of MeCP2 Function in Drosophila , 2008, PLoS genetics.

[24]  Alcino J. Silva,et al.  Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis , 2008, Nature Medicine.

[25]  Stephen T. C. Wong,et al.  MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription , 2008, Science.

[26]  H. Lane,et al.  Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function , 2008, The Journal of Neuroscience.

[27]  J. Brotchie,et al.  Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice. , 2008, Human molecular genetics.

[28]  A. Percy.  Rett Syndrome: Recent Research Progress , 2008, Journal of child neurology.

[29]  D. Gutmann,et al.  Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex , 2008, Annals of neurology.

[30]  C. Martínez-Cué,et al.  Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome , 2008, Neuroscience Letters.

[31]  Liang Zhang,et al.  The MeCP2‐null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability , 2008, Hippocampus.

[32]  E. Kavalali,et al.  Activity-Dependent Suppression of Miniature Neurotransmission through the Regulation of DNA Methylation , 2008, The Journal of Neuroscience.

[33]  S. Zanella,et al.  Oral treatment with desipramine improves breathing and life span in Rett syndrome mouse model , 2008, Respiratory Physiology & Neurobiology.

[34]  Mark F. Bear,et al.  Correction of Fragile X Syndrome in Mice , 2007, Neuron.

[35]  Christian Rosenmund,et al.  MeCP2 Controls Excitatory Synaptic Strength by Regulating Glutamatergic Synapse Number , 2007, Neuron.

[36]  J. Aimone,et al.  Mecp2 deficiency leads to delayed maturation and altered gene expression in hippocampal neurons , 2007, Neurobiology of Disease.

[37]  N. Nag,et al.  Behavioral and anatomical abnormalities in Mecp2 mutant mice: A model for Rett syndrome , 2007, Neuroscience.

[38]  Fabian Fernandez,et al.  Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome , 2007, Nature Neuroscience.

[39]  J. Roux,et al.  Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome , 2007, The European journal of neuroscience.

[40]  A. Bird,et al.  Reversal of Neurological Defects in a Mouse Model of Rett Syndrome , 2007, Science.

[41]  R. Jaenisch,et al.  Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2 , 2007, Proceedings of the National Academy of Sciences.

[42]  S. Kudo,et al.  Methyl CpG-Binding Protein 2 (a Mutation of Which Causes Rett Syndrome) Directly Regulates Insulin-Like Growth Factor Binding Protein 3 in Mouse and Human Brains , 2007, Journal of neuropathology and experimental neurology.

[43]  Eric C. Griffith,et al.  Brain-Specific Phosphorylation of MeCP2 Regulates Activity-Dependent Bdnf Transcription, Dendritic Growth, and Spine Maturation , 2006, Neuron.

[44]  J. Christodoulou,et al.  Predictors of seizure onset in Rett syndrome. , 2006, The Journal of pediatrics.

[45]  H. Zoghbi,et al.  MeCP2 dysfunction in Rett syndrome and related disorders. , 2006, Current opinion in genetics & development.

[46]  P. Tam,et al.  Mecp2 deficiency is associated with learning and cognitive deficits and altered gene activity in the hippocampal region of mice. , 2006, Brain : a journal of neurology.

[47]  A. Bird,et al.  Genomic DNA methylation: the mark and its mediators. , 2006, Trends in biochemical sciences.

[48]  James H. Eubanks,et al.  Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome , 2006, Neurobiology of Disease.

[49]  H. Zoghbi,et al.  Learning and Memory and Synaptic Plasticity Are Impaired in a Mouse Model of Rett Syndrome , 2006, The Journal of Neuroscience.

[50]  Laurent Villard,et al.  Mecp2 Deficiency Disrupts Norepinephrine and Respiratory Systems in Mice , 2005, The Journal of Neuroscience.

[51]  Y. Nomura.  Early behavior characteristics and sleep disturbance in Rett syndrome , 2005, Brain and Development.

[52]  B. Hagberg.  Rett Syndrome: Long-Term Clinical Follow-Up Experiences Over Four Decades , 2005, Journal of child neurology.

[53]  Rudolf Jaenisch,et al.  Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Michael Grunstein,et al.  Histone H2B ubiquitylation controls processive methylation but not monomethylation by Dot1 and Set1. , 2005, Molecular cell.

[55]  T. Ichikawa,et al.  Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. , 2005, Journal of neuropathology and experimental neurology.

[56]  Yan Wang,et al.  Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X Syndrome , 2005, Neuron.

[57]  Noriyuki Kishi,et al.  MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions , 2004, Molecular and Cellular Neuroscience.

[58]  H. Zoghbi,et al.  Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. , 2004, Human molecular genetics.

[59]  G. Ronnett,et al.  The transcriptional repressor Mecp2 regulates terminal neuronal differentiation , 2004, Molecular and Cellular Neuroscience.

[60]  F. Khuri,et al.  Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer , 2004, Oncogene.

[61]  R. Jaenisch,et al.  Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Daisuke Hattori,et al.  DNA Methylation-Related Chromatin Remodeling in Activity-Dependent Bdnf Gene Regulation , 2003, Science.

[63]  Eric C. Griffith,et al.  Derepression of BDNF Transcription Involves Calcium-Dependent Phosphorylation of MeCP2 , 2003, Science.

[64]  Juan I. Young,et al.  Mice with Truncated MeCP2 Recapitulate Many Rett Syndrome Features and Display Hyperacetylation of Histone H3 , 2002, Neuron.

[65]  J. LaSalle,et al.  Quantitative localization of heterogeneous methyl-CpG-binding protein 2 (MeCP2) expression phenotypes in normal and Rett syndrome brain by laser scanning cytometry. , 2001, Human molecular genetics.

[66]  G. Jamal,et al.  Characterisation of breathing and associated central autonomic dysfunction in the Rett disorder , 2001, Archives of disease in childhood.

[67]  R. Jaenisch,et al.  Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice , 2001, Nature Genetics.

[68]  D. Glaze,et al.  Substance P immunoreactivity in Rett syndrome. , 2000, Pediatric neurology.

[69]  H. Zoghbi,et al.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 , 1999, Nature Genetics.

[70]  G. Wenk,et al.  Altered Cholinergic Function in the Basal Forebrain of Girls with Rett Syndrome , 1999, Neuropediatrics.

[71]  R. Vanhala,et al.  Levels of cerebrospinal fluid nerve‐growth factor differ in infantile autism and Rett syndrome , 1999, Developmental medicine and child neurology.

[72]  B. Antalffy,et al.  Decreased Dendritic Branching in Frontal, Motor and Limbic Cortex in Rett Syndrome Compared with Trisomy 21 , 1998, Journal of neuropathology and experimental neurology.

[73]  T. Matsuishi,et al.  Decreased cerebrospinal fluid levels of substance P in patients with Rett syndrome , 1997, Annals of neurology.

[74]  G. Wenk.  RETT SYNDROME: NEUROBIOLOGICAL CHANGES UNDERLYING SPECIFIC SYMPTOMS , 1997, Progress in Neurobiology.

[75]  A. Bird,et al.  MeCP2 Is a Transcriptional Repressor with Abundant Binding Sites in Genomic Chromatin , 1997, Cell.

[76]  A. Reiss,et al.  Neuroanatomy in Rett syndrome , 1997, Neurology.

[77]  R. Riikonen,et al.  High levels of cerebrospinal fluid glutamate in Rett syndrome. , 1996, Pediatric neurology.

[78]  D. Lindholm,et al.  Low Levels of Nerve Growth Factor in Cerebrospinal Fluid of Children With Rett Syndrome , 1996, Journal of child neurology.

[79]  S. L. Mobley,et al.  Choline acetyltransferase activity and vesamicol binding in Rett syndrome and in rats with nucleus basalis lesions , 1996, Neuroscience.

[80]  B. Antalffy,et al.  Selective Dendritic Alterations in the Cortex of Rett Syndrome , 1995, Journal of neuropathology and experimental neurology.

[81]  S. Cross,et al.  Genetic and physical mapping of a gene encoding a methyl CpG binding protein, Mecp2, to the mouse X chromosome. , 1994, Genomics.

[82]  A. Bird,et al.  Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. , 1993, Nucleic acids research.

[83]  A. Reiss,et al.  Neuroanatomy of Rett syndrome: A volumetric imaging study , 1993, Annals of neurology.

[84]  D. D. del Junco,et al.  The pattern of growth failure in Rett syndrome. , 1993, American journal of diseases of children.

[85]  C. Gillberg,et al.  Elevated CSF glutamate in Rett syndrome. , 1992, Neuropediatrics.

[86]  A. Bird,et al.  Purification, sequence, and cellular localization of a novel chromosomal protein that binds to Methylated DNA , 1992, Cell.

[87]  A. Percy.  Neurochemistry of the Rett syndrome. , 1992, Brain & development.

[88]  M. Segawa,et al.  Polysomnography in the Rett syndrome. , 1992, Brain & development.

[89]  M. Segawa,et al.  The pathophysiology of the Rett syndrome from the standpoint of polysomnography , 1990, Brain and Development.

[90]  L. Svennerholm,et al.  CSF and urine biogenic amine metabolites in Rett syndrome , 1990, Clinical genetics.

[91]  H. Zoghbi,et al.  Cerebrospinal fluid biogenic amines and biopterin in rett syndrome , 1989, Annals of neurology.

[92]  H. Zoghbi,et al.  Reduction of biogenic amine levels in the Rett syndrome. , 1985, The New England journal of medicine.

[93]  Jean Aicardi,et al.  A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: Report of 35 cases , 1983, Annals of neurology.

[94]  A Rett,et al.  [On a unusual brain atrophy syndrome in hyperammonemia in childhood]. , 1966, Wiener medizinische Wochenschrift.

[95]  A. Olowoyeye,et al.  Gene therapy for sickle cell disease. , 2010, The Cochrane database of systematic reviews.

[96]  C. Liapi,et al.  Genetic basis and gene therapy trials for thyroid cancer. , 2010, Cancer genomics & proteomics.

[97]  E. Valdizán,et al.  Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. , 2010, Journal of Alzheimer's disease : JAD.

[98]  M. Missler,et al.  Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome. , 2008, Journal of neurophysiology.

[99]  E. Weeber,et al.  Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of αCaMKII inhibitory phosphorylation , 2007, Nature Neuroscience.

[100]  Wh Sit,et al.  Cancer Genomics & Proteomics , 2007 .

[101]  P. Riederer,et al.  Reduced concentrations and increased metabolism of biogenic amines in a single case of Rett-syndrome: apostmortem brain study , 2005, Journal of Neural Transmission.

[102]  Jan-Fang Cheng,et al.  Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome , 2005, Nature Genetics.

[103]  D. Armstrong.  Neuropathology of Rett syndrome. , 2002, Mental retardation and developmental disabilities research reviews.

[104]  E. Hoffman,et al.  Associations between MeCP2 mutations, X-chromosome inactivation, and phenotype. , 2002, Mental retardation and developmental disabilities research reviews.

[105]  R. Hastings,et al.  Behavioural and emotional features in Rett syndrome. , 2001, Disability and rehabilitation.

[106]  A. Bird,et al.  A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome , 2001, Nature Genetics.

[107]  S. Cross,et al.  Gene silencing by methyl-CpG-binding proteins. , 1998, Novartis Foundation symposium.

[108]  A. Dahlström,et al.  Morphological study of neocortical areas in Rett syndrome , 1996, Acta Neuropathologica.

[109]  A. Bird,et al.  Identification and Characterization of a Family of Mammalian Methyl-CpG Binding Proteins , 2022 .